240 related articles for article (PubMed ID: 30036051)
1. Cichoric Acid Prevents Free-Fatty-Acid-Induced Lipid Metabolism Disorders via Regulating Bmal1 in HepG2 Cells.
Guo R; Zhao B; Wang Y; Wu D; Wang Y; Yu Y; Yan Y; Zhang W; Liu Z; Liu X
J Agric Food Chem; 2018 Sep; 66(37):9667-9678. PubMed ID: 30036051
[TBL] [Abstract][Full Text] [Related]
2. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model.
Im AR; Kim YH; Lee HW; Song KH
J Med Food; 2016 May; 19(5):495-503. PubMed ID: 27152979
[TBL] [Abstract][Full Text] [Related]
3. Effects of
Mun J; Park J; Yoon HG; You Y; Choi KC; Lee YH; Kim K; Lee J; Kim OK; Jun W
J Med Food; 2019 Dec; 22(12):1262-1270. PubMed ID: 31834842
[TBL] [Abstract][Full Text] [Related]
4. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
Zeng L; Tang W; Yin J; Feng L; Li Y; Yao X; Zhou B
Cell Physiol Biochem; 2016; 40(3-4):453-464. PubMed ID: 27889747
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol Maintains Lipid Metabolism Homeostasis via One of the Mechanisms Associated with the Key Circadian Regulator Bmal1.
Li J; Wei L; Zhao C; Li J; Liu Z; Zhang M; Wang Y
Molecules; 2019 Aug; 24(16):. PubMed ID: 31408938
[TBL] [Abstract][Full Text] [Related]
6. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
7. Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease.
Maruyama H; Kiyono S; Kondo T; Sekimoto T; Yokosuka O
Int J Med Sci; 2016; 13(3):169-78. PubMed ID: 26941577
[TBL] [Abstract][Full Text] [Related]
8. Nobiletin protects against insulin resistance and disorders of lipid metabolism by reprogramming of circadian clock in hepatocytes.
Qi G; Guo R; Tian H; Li L; Liu H; Mi Y; Liu X
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jun; 1863(6):549-562. PubMed ID: 29501626
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of cichoric acid on H
Ma J; Li M; Kalavagunta PK; Li J; He Q; Zhang Y; Ahmad O; Yin H; Wang T; Shang J
Biomed Pharmacother; 2018 Aug; 104():679-685. PubMed ID: 29803928
[TBL] [Abstract][Full Text] [Related]
10. Mulberry anthocyanins inhibit oleic acid induced lipid accumulation by reduction of lipogenesis and promotion of hepatic lipid clearance.
Chang JJ; Hsu MJ; Huang HP; Chung DJ; Chang YC; Wang CJ
J Agric Food Chem; 2013 Jun; 61(25):6069-76. PubMed ID: 23731091
[TBL] [Abstract][Full Text] [Related]
11. Chicoric acid attenuate a nonalcoholic steatohepatitis by inhibiting key regulators of lipid metabolism, fibrosis, oxidation, and inflammation in mice with methionine and choline deficiency.
Kim M; Yoo G; Randy A; Kim HS; Nho CW
Mol Nutr Food Res; 2017 May; 61(5):. PubMed ID: 27981809
[TBL] [Abstract][Full Text] [Related]
12. β-Caryophyllene attenuates palmitate-induced lipid accumulation through AMPK signaling by activating CB2 receptor in human HepG2 hepatocytes.
Kamikubo R; Kai K; Tsuji-Naito K; Akagawa M
Mol Nutr Food Res; 2016 Oct; 60(10):2228-2242. PubMed ID: 27234712
[TBL] [Abstract][Full Text] [Related]
13. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.
Kang OH; Kim SB; Mun SH; Seo YS; Hwang HC; Lee YM; Lee HS; Kang DG; Kwon DY
Int J Mol Med; 2015 Mar; 35(3):803-9. PubMed ID: 25605057
[TBL] [Abstract][Full Text] [Related]
14. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
15. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3β and γ differentially regulate peroxisome proliferator activated receptor γ2 transactivation and hepatic lipid metabolism.
Park S; Yoo S; Kim J; An HT; Kang M; Ko J
Biochim Biophys Acta; 2015 Oct; 1849(10):1237-47. PubMed ID: 26260846
[TBL] [Abstract][Full Text] [Related]
18. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
[TBL] [Abstract][Full Text] [Related]
20. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
Jiang Y; Chen L; Wang H; Narisi B; Chen B
J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
